Delta-Fly Pharma, Inc. (4598.T)
JPY 490.0
(8.41%)
JPY 490.0
(8.41%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.41 Billion JPY | -67.83% |
| 2022 | -844.34 Million JPY | 33.44% |
| 2021 | -1.26 Billion JPY | 39.27% |
| 2020 | -2.08 Billion JPY | -18421.16% |
| 2019 | 11.4 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -755 Million JPY | 15.39% |
| 2023 Q4 | -1.41 Billion JPY | 17.98% |
| 2023 Q3 | -1.72 Billion JPY | -295.54% |
| 2023 Q2 | -436.81 Million JPY | 38.86% |
| 2023 Q1 | -714.39 Million JPY | 15.39% |
| 2023 FY | -1.41 Billion JPY | -67.83% |
| 2022 Q3 | 180 Million JPY | 126.96% |
| 2022 Q2 | -667.7 Million JPY | 0.0% |
| 2022 Q4 | -844.34 Million JPY | -569.08% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 290.784% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | -24.968% |
| GNI Group Ltd. | -17.93 Billion JPY | 92.098% |
| Linical Co., Ltd. | -4.46 Billion JPY | 68.251% |
| Trans Genic Inc. | -221.16 Million JPY | -540.715% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 67.75% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 70.416% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 198.851% |
| AnGes, Inc. | -3.79 Billion JPY | 62.687% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -236.749% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 105.689% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -184.463% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -203.864% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 47.635% |
| CanBas Co., Ltd. | -1.88 Billion JPY | 24.952% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -44.283% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 58.285% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | -36.973% |
| Kidswell Bio Corporation | 343.58 Million JPY | 512.429% |
| PeptiDream Inc. | 3.29 Billion JPY | 143.046% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -45.699% |
| Ribomic Inc. | -2.09 Billion JPY | 32.513% |
| SanBio Company Limited | -3.78 Billion JPY | 62.608% |
| Healios K.K. | -2.19 Billion JPY | 35.294% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -49.976% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 45.999% |
| StemRIM | -8.41 Billion JPY | 83.15% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 69.743% |
| FunPep Company Limited | -1.79 Billion JPY | 20.984% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 33.673% |
| Stella Pharma Corporation | -1.11 Billion JPY | -26.591% |
| TMS Co., Ltd. | -3.44 Billion JPY | 58.886% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 74.494% |
| Cuorips Inc. | -5.56 Billion JPY | 74.518% |
| K Pharma,Inc. | -3.26 Billion JPY | 56.617% |
| Takara Bio Inc. | -32.2 Billion JPY | 95.6% |
| ReproCELL Incorporated | -2.93 Billion JPY | 51.785% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -114.395% |
| StemCell Institute Inc. | -2.83 Billion JPY | 50.046% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | 31.422% |
| CellSeed Inc. | -2.01 Billion JPY | 29.571% |